Glioma

REVIEW
Year
: 2022  |  Volume : 5  |  Issue : 1  |  Page : 5--11

The diverse landscape of histone-mutant pediatric high-grade gliomas: A narrative review


Evan Lubanszky1, Cynthia Hawkins2 
1 The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
2 The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children; Department of Laboratory Medicine and Pathobiology, University of Toronto; Division of Pathology, Hospital for Sick Children, Toronto, ON, Canada

Correspondence Address:
Dr. Cynthia Hawkins
Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital For Sick Children, 555 University Avenue Toronto, ON, M5g 1x8
Canada

Pediatric high-grade gliomas (pHGGs) are the leading cause of tumor-related death in children, with diffuse midline gliomas representing the worst prognoses. Despite decades of clinical trials, no effective treatment has been found, and we are in desperate need of novel therapeutics. The discovery of highly recurrent histone H3 mutations in pHGGs represents a major breakthrough in our understanding of tumor initiation and development. In this review, we summarize our current knowledge of the molecular pathology of these tumors, including their genomic/epigenetic alterations, mechanism of action, and partner mutations contributing to tumor progression.


How to cite this article:
Lubanszky E, Hawkins C. The diverse landscape of histone-mutant pediatric high-grade gliomas: A narrative review.Glioma 2022;5:5-11


How to cite this URL:
Lubanszky E, Hawkins C. The diverse landscape of histone-mutant pediatric high-grade gliomas: A narrative review. Glioma [serial online] 2022 [cited 2022 Jun 29 ];5:5-11
Available from: http://www.jglioma.com/article.asp?issn=2589-6113;year=2022;volume=5;issue=1;spage=5;epage=11;aulast=Lubanszky;type=0